Quaking-induced conversion of prion protein on a thermal mixer accelerates detection in brains infected with transmissible spongiform encephalopathy agents

Effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by nigrostriatal degeneration and aggregation of α-synuclein (α-Syn) with accumulation of insoluble aggregates in Lewy bodies. Familial mutations in α-Syn are associated with the development of PD. Accumulation of insoluble aggregates results in neuronal toxicity. Identification of compounds that inhibit seeding activity of α-Syn is of great importance. Here we investigate the potential of H2S donor, sodium hydrosulfide (NaHS), to inhibit α-Syn aggregation. We examined the effect of NaHS on fibril growth kinetics and the structural change of α-Syn fibrils formed by self-seeding and cross-seeding of wild-type (wt) and PD familial α-Syn mutations. NaHS slowed both self- and cross-seeded A53T α-Syn fibril formation but not wild-type fibril formation. We observed a decrease in the formed fibril length in vitro. We examined the effect on fibril formation within cells. NaHS significantly reduced the number and filament length of formed oligomers in an α-Syn overexpressing cell model. Furthermore, NaHS rescued viability of A53T α-Syn overexpressing cells seeded with wt- and mutant preformed fibrils. These results support a conformation-specific effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability which deserves further exploration for therapeutic potential.

Bovine spongiform encephalopathy: A review of current knowledge and challenges

Bovine spongiform encephalopathy (BSE), also referred to as mad cow disease, is a chronic degenerative disease that affects the central nervous system. BSE is caused by a misfolded isoform of the prion protein, a widely expressed glycoprotein. The illness is referred to as Variant Creutzfeldt-Jakob disease (vCJD) in humans. In the United Kingdom (UK), BSE in cattle was first discovered in 1986. Based on epidemiological data, it appears that animal feed containing tainted meat and bone meal (MBM) as a source of meat protein is the common cause of the BSE outbreak in the UK. Clinical indicators in cows include irregular body posture, incoordination, difficulty in standing, weight loss, and temperamental changes, including agitation and hostility. Feeding livestock MBM obtained from BSE-infected livestock contaminated with BSE prions is the only known risk factor for BSE development. Strong evidence linking BSE to human transmission and a variant type of CJD has brought the disease to the attention of many countries. Screening living animals for BSE is challenging. In most cases, suspected animals are usually killed. Typically, the central nervous system is examined for prions to diagnose this illness. There is currently no robust treatment for BSE. The prevention of BSE can be achieved by avoiding the feeding of susceptible animals with ruminant tissues that might carry prions.

Bovine spongiform encephalopathy: A review of current knowledge and challenges

Bovine spongiform encephalopathy (BSE), also referred to as mad cow disease, is a chronic degenerative disease that affects the central nervous system. BSE is caused by a misfolded isoform of the prion protein, a widely expressed glycoprotein. The illness is referred to as Variant Creutzfeldt-Jakob disease (vCJD) in humans. In the United Kingdom (UK), BSE in cattle was first discovered in 1986. Based on epidemiological data, it appears that animal feed containing tainted meat and bone meal (MBM) as a source of meat protein is the common cause of the BSE outbreak in the UK. Clinical indicators in cows include irregular body posture, incoordination, difficulty in standing, weight loss, and temperamental changes, including agitation and hostility. Feeding livestock MBM obtained from BSE-infected livestock contaminated with BSE prions is the only known risk factor for BSE development. Strong evidence linking BSE to human transmission and a variant type of CJD has brought the disease to the attention of many countries. Screening living animals for BSE is challenging. In most cases, suspected animals are usually killed. Typically, the central nervous system is examined for prions to diagnose this illness. There is currently no robust treatment for BSE. The prevention of BSE can be achieved by avoiding the feeding of susceptible animals with ruminant tissues that might carry prions.

The utility of bank voles for studying prion disease

The transmission of prions between species is typically an inefficient process due to the species barrier, which represents incompatibility between prion seed and substrate molecules. Bank voles (Myodes glareolus) are an exception to this rule, as they are susceptible to a diverse range of prion strains from many different animal species. In particular, bank voles can be efficiently infected with most types of human prions and have played a critical role in validating variably protease-sensitive prionopathy (VPSPr) and certain forms of Gerstmann-Sträussler-Scheinker (GSS) disease as bona fide prion disorders rather than non-transmissible proteinopathies. The bank vole prion protein (BVPrP) confers a "universal prion acceptor" phenotype when expressed in mice and when used as a substrate for in vitro prion amplification assays, indicating that the unique prion transmission properties of bank voles are mediated by BVPrP. Over-expression of BVPrP in mice can also promote the spontaneous development of prion disease, indicating that BVPrP is intrinsically prone to both spontaneous and template-directed misfolding. Here, we discuss the utility of bank voles and BVPrP for prion research and how they have provided new tools for establishing rapid animal bioassays, modeling spontaneous prion disease, standardizing prion diagnostics, and understanding the molecular basis of the species barrier.

Processing bovine intestinal mucosa to active heparin removes spiked BSE agent

Heparin is an anticoagulant sourced from animal tissues. In the 1990s, bovine-sourced heparin was withdrawn from the U.S. market due to a theoretical concern that the bovine spongiform encephalopathy (BSE) agent might contaminate crude heparin and spread to humans as variant Creutzfeldt-Jakob disease. Only porcine intestinal heparin is now marketed in the U.S. FDA has encouraged the reintroduction of bovine heparin. We applied a scaled-down laboratory model process to produce heparin as an active pharmaceutical ingredient (API) starting from bovine intestinal mucosa. The process consisted of two phases. To model the first phase, we applied enzymatic proteolysis, anionic resin separation and methanol precipitation of crude heparin. Bovine intestinal mucosa was spiked with BSE or scrapie agents. We assayed BSE- or scrapie-associated prion protein (PrP^TSE) using the Real-Time Quaking-Induced Conversion (RT-QuIC) assay at each step. The process reduced PrP^TSE by 4 log₁₀ and 6 log₁₀ from BSE-spiked and scrapie-spiked mucosa, respectively. To model the entire process, we spiked mucosa with scrapie agent and produced heparin API, reducing PrP^TSE by 6.7 log₁₀. The purification processes removed large amounts of PrP^TSE from the final products. Heparin purification together with careful sourcing of raw materials should allow safely reintroducing bovine heparin in the U.S.